Sunshine Biopharma Inc. — Form S-1
Filed November 18, 2026 · analyzed by the Registration Agent
S-1
▲ Likely positive
significance 72/100
What the filing says
Sunshine Biopharma Inc. (market cap ~$7.1M) executed a 1-for-20 reverse stock split effective October 20, 2026, combining every 20 shares into 1 share with fractional shares rounded up. Concurrently, the company filed a Form S-1 registration statement to offer 31,087,198 shares of common stock to the public. The reverse split reduces share count and nominally raises per-share price to meet listing standards; the S-1 seeks capital via primary offering.
Why this rating
Reverse split + IPO is material for $7.1M company—restructuring and capital raise could transform trajectory. However, outcome depends on demand and dilution; execution risk is high.
Tradability signal
NO TRADE
No trade: price $0.03 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $0.03 | +10 min · unknown $0.03 ▲ 0.00% | +30 min · unknown $0.03 ▲ 0.00% | +1 hr · unknown $0.03 ▲ 0.00% | +4 hrs · unknown $0.03 ▲ 0.00% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.